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Introduction: vascular endothelial growth factor (VEGF) and tumour necrosis factor alpha (TNF) have been specifically
implicated in the tissue damage associated with chronic venous disease (CVD). Furthermore, production of both factors
is known to be upregulated in vessel wall cells subject to hypertension. The aim of this study was to determine the local
venous levels of VEGF and TNF in limbs with venous ulcers before and after treatment with graduated compression.
Patients and methods: eight patients with venous ulcers and 8 patients with varicose veins only were included in the
study. For ulcer patients, serum samples were taken from the superficial veins in lower limbs and repeated after 4 weeks
of treatment with 4-layered graduated compression. Serum from the arms of the same patients served as controls.
Determination of the concentrations of VEGF and TNF proteins were performed with sandwich enzyme-linked
immunosorbent assays.
Results: both groups of patients had elevated levels of VEGF and TNF. In patients with venous ulcers there was a
reduction in the levels of both cytokines to below control values with treatment. These changes correlated with healing
of the ulcers as determined by reduction in ulcer size.
Conclusion: these data, for the first time, suggest a central role for both TNF and VEGF in the pathogenesis of venous
ulceration which may constitute a causative link between venous hypertension and tissue pathology.
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Introduction compression is thought to promote ulcer healing by
acting to restore venous tone, reducing reflux and
ambulatory venous pressures and normalising the ven-Chronic venous disease is the commonest but least
ous haemodynamics.5 Multilayer bandaging systemsunderstood cause of lower leg ulceration. The tissue
based on the Charing Cross model achieve the greatestchanges and ulceration which develop in patients with
level of sustained graduated pressure and are acceptedchronic venous disease (CVD) are strongly correlated
as effective methods of promoting healing of venouswith elevated ambulatory pressures (AVP) in the su-
ulcers.6perficial veins.1 A number of theories have attempted
Recently, in vivo studies of systemic essential hyper-to explain this association. Accumulation and ac-
tension,7 pre-eclampsia8 and pulmonary hypertension9tivation of sequestered white cells in affected limbs
have shown an associated elevation in serum cyto-forms the basis of the currently favoured theories.2,3
kines, notably vascular endothelial growth factorNone of these, however, explain the relationship be-
(VEGF) and tumour necrosis factor alpha (TNF).tween elevated AVP and tissue pathology in CVD.
Elevated serum levels of VEGF have also been dem-There is as yet no established causative link between
onstrated in the limbs of patients with chronic venousvenous hypertension and tissue disease.2
disease (CVD).10 It has further been shown, using in-Compression treatment is the first line therapy for
vitro models, that endothelial cells subject to abnormalvenous ulcers and is effective in achieving healing of
sheer forces and hypertension display altered functionulcers in the majority of patients. Patients with smaller
and cytokine secretion.11–15 This is accomplishedulcers present for shorter durations have the greatest
through a process of mechanotransduction, the mech-response to this treatment and healing rates of up to
anism whereby cells transduce mechanical stimuli into95% have been reported in these groups.4 Graduated
an intracellular signal and biological response.13 There
is as yet no published data on the effect of venous
hypertension on cytokine secretion from the vascular∗ Please address all correspondence to: W. P. Joyce, Consultant
Surgeon, Cavan General Hospital, Cavan, Ireland. wall.
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Table 1. Patient characteristics. icose veins but without ulceration (CEAP clinical class
2) were included for comparison. All had DuplexMedian (range)
confirmed long saphenous vein (LSV) incompetence.
Number/sex 8 (5 M/3 F)
Age (years) 67 (62–82)
Duration of ulcer (months) 6 (1–12) Serum samplingUlcer size (T0) (square centimetres) 2.9 (1–5)
Ulcer size (T1) (square centimetres) 1.4 (0–3)
Weeks to complete healing from T0 10 (4–12) Serum samples were taken from the superficial veins
Duplex reflux (no./percentage) in the lower limb in the ulcer vicinity (immediatelySuperficial 8 (100%)
proximal to the ulcer). Samples were repeated onceDeep 2 (25%)
ICP 8 (100%) during the treatment period. The repeat samples were
taken after between 4 and 6 weeks of treatment with
4-layered graduated compression when the ulcers ex-It is our hypothesis that superficial venous hyper-
hibited healing. This time point was chosen, as it istension produces in a local alteration in cytokine pro-
the timeframe in which a positive response to therapyduction resulting in an alteration of the cytokine
has been shown to manifest as a reduction in ulcercontent of the microcirculation, tissues and wound
size.4 Patients who demonstrate reduction in ulcer sizemicroenvironment in limbs with CVD. We further
at this point are those in whom compression therapy ishypothesise that these changes are reversible upon
effective as a method of treatment. This is presumablyreduction of venous hypertension with compression
because this group of patients represents those whotreatment.
are compliant and whose venous haemodynamics areA number of cytokines with established roles in
beneficially altered by compression. Healing wasangiogenesis and wound healing are among those
measured as a reduction in ulcer size using com-whose production have been shown to be stimulated
puterised planimetry. Patients with varicose veins onlyby elevated pressures. From the currently available
had single samples taken. In these patients serumdata those cytokines which are likely to be of import-
samples were taken from superficial varicosities in theance in CVD include VEGF and TNF.
distribution of the LSV in the lower leg.The aim of this study was to determine the serum
In all sampling groups control samples from thelevels of VEGF and TNF in the superficial veins of
patients’ median cubital vein were taken sim-patients with venous ulceration at first presentation
ultaneously to serve as controls. Blood samples wereand again after a period of treatment with 4-layer
collected in plain tubes and centrifuged at 2000 rpmgraduated compression.
for 10 min to obtain serum fraction. Samples were then
stored at −80 °C until assayed.
Methods
Cytokine ELISA
Patient selection
Determination of the concentrations of VEGF and
Ethical approval for this study was granted by the TNF proteins were performed with sandwich en-
North Eastern Health Board of Ireland. Eight patients zyme-linked immunosorbent assays (R&D Systems,
with non-healing ulcers were selected from a spe- U.K.). The assays were performed according to the
cialised ulcer clinic before institution of treatment. manufacturer’s protocol. Results were obtained from
Patients were excluded if they evidence of peripheral an ELISA reader and calculated using statistical soft-
arterial disease as determined by ankle brachial pres- ware programme “Analyse-it for Microsoft Excel”,
sure indices (ABIs) of <0.8. Patients with diabetes or Leeds, U.K. Statistical analyses were carried out using
rheumatoid disease were also excluded. the Wilcoxin Signed Ranks test. p values of <0.05 were
All patients had duplex confirmed CVD. Venous considered significant.
reflux was determined using a Hewlett Packard Sonos
500 scanner with venous imaging software. Reflux was
defined as reversed flow lasting greater than 0.5 s in Results
the superficial, deep or perforator veins according to
recent consensus guidelines.16 All eight patients (5 male/3 female) with venous ulcers
completed the study. In all cases patients exhibitedUlcer size ranged from 1–5 cm2 and had been present
for a median of 6 months (Table 1). healing as determined by a reduction in the ulcer at
the time of repeat sampling. All ulcers had completelyA further group of 8 patients presenting with var-
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of both VEGF to below control values with treatment
(Figs 1 and 2).
Serum from patients with varicose veins but no
ulceration (CEAP 2) also showed elevations in the
levels of VEGF cytokines in all cases (Fig. 1). TNF
levels in varicose vein patients were also elevated but
failed to reach statistical significance compared to the
systemic controls at the start of treatment (Fig. 2).
Discussion
This study, for the first time, demonstrates a significant
elevation in VEGF and TNF in patients presenting
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with venous ulceration and shows that these levels
Fig. 1. Serum concentrations of VEGF in pg/ml. Values for each are reduced with effective treatment.
patient are shown as (-) with median values marked as ((). Difference
The significance of elevated VEGF concentrations inbetween T0 samples and controls are significant at p=0.0078, T1
<T0, p=0.005; V Veins>control, p=0.0078. Wilcoxin signed ranks limbs with CVD is more readily appreciated when it
test. is considered that this cytokine was originally named
Vascular Permeability Factor because of its potent
effect on the permeability of the vascular wall. In-
creased vascular permeability may play an important
role in tissue oedema, fibrin deposition and lipo-
dermatosclerosis in CVD.
TNF is a well-characterised cytokine which has
been strongly implicated in tissue damage associated
with CVD.17 Endothelial cells can be stimulated to
produce TNF.18 Serum TNF is increased in hyper-
tensive states including essential hypertension and
pre-eclampsia. TNF not only inhibits the growth of
endothelial cells in vitro but has been demonstrated to
selectively inhibit the pro-angiogenic effect of VEGF
and synergistically increase its effect on permea-
bility.19,20 Furthermore, it inhibits anti-coagulatory
mechanisms and promotes thrombotic processes and
therefore plays an important role in pathological pro-
cesses such as venous thromboses.
The study demonstrates an abnormal cytokine en-
vironment in the serum of patients with venous ul-
ceration and a reversal with successful therapy. The
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findings are consistent with those of a number of
recent studies in patients with various hypertensiveFig. 2. Serum concentrations of TNF in pg/ml. Values for each
patient are shown as (-) with median values marked as ((). Difference states and particularly with the data presented by
between T0 samples and controls are significant at p=0.0078, T1 Shoab et al.10 who showed a small but significant rise
<T0, p=0.005; TNF in varicose Veins> Control but this is not
in VEGF with experimental hypertension in patientssignificant at p=0.84. Difference between TNF in varicose veins
and treated ulcers did not reach significance, p=0.078 using Wilcoxin with CVD. In vitro work, showing cytokine production
signed ranks test. as an intracellular biological response to altered mech-
anical forces, suggest hypertension induced me-
chanotransduction as a potential source of cytokinesre-epithelialised within 8 weeks of samples taken in
the healing phase (Table 1). in these conditions. Our conclusions are based on
venous ulceration occurring as a consequence of in-All patients had significantly elevated levels of
VEGF in samples during the non-healing phase (Fig. 1). creased pressure in the superficial veins and healing
of ulceration being promoted by effective reductionSimilarly, TNF was elevated in non-healing samples
(Fig. 2).In each case there was a reduction in the levels of these elevated pressures. The study hypothesis at-
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tempts to provide an explanation of how the hyper- regulation of cytokine production in hypertensive
veins will be necessary to establish this me-tension might cause inflammatory changes and ul-
chanotransduction as a causative factor in the tissueceration in the tissues. Both of the cytokines measured
damage associated with CVD.in this are recognised as having important effects
on mediating inflammation and in the regulation of
wound healing. Release of vasoactive and in-
flammatory mediators such as VEGF and TNF in
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